AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7788007
Drug: L-thyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-thyroxine (L-T4) treatment for a period of 2.8 (2.8) years with a mean daily dose of 77 (18) micrograms/m2
Trial: 7788007
Drug: L-thyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-thyroxine (L-T4) treatment
Trial: 23427865
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 0.01 mL/min
Trial: 23427865
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 0.5 mL/min
Trial: 11551130
Drug: Cisplatin-containing regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin-containing regimens concurrent with radiation therapy
Trial: 8011000
Drug: Fluorocarbon-free GTN
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorocarbon-free GTN pump spray with high ethanol content (TH)
Trial: 376236
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Heparin therapy
Trial: 31816306
Drug: Outpatient ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Outpatient ibuprofen plus hydrocodone‐acetaminophen (opioid, n=85)
Trial: 23670707
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg/day
Trial: 25217230
Drug: Whole-brain radiotherapy
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-brain radiotherapy in primary therapy of PCNSL
Trial: 21343556
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg (subcutaneous, monthly)
Trial: 21343556
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg (intravenous, dose adjusted for renal impairment)
Trial: 9176034
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (200 mg zinc sulphate, 500 mg ascorbic acid, 600 mg alpha-tocopherol, 30 mg beta-carotene daily for 8 weeks)
Trial: 2858421
Drug: Reproterol (0.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol (0.28 mg/kg)
Trial: 2858421
Drug: Salbutamol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.1 mg/kg)
Trial: 26787796
Drug: i-gel SGA
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel SGA
Trial: 22670598
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg every 6 h)
Trial: 20492655
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg plus simvastatin 20 mg (EZ + simva 10/20 mg)
Trial: 19167588
Drug: ezetimibe +
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ezetimibe + pravastatin 10 to 40 mg/d
Trial: 15278749
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg/day) for 12 months
Trial: 7863047
Drug: Continuous Ambulatory
RxNorm normalized name: Continuous ambulatory peritoneal dialysis solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Ambulatory Oxygen Therapy (CAOT) - Group B
Trial: 172561
Drug: Formalin‐inactivated decavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalin‐inactivated decavalent rhinovirus vaccine 1
Trial: 29672740
Drug: Vadadustat 450
RxNorm normalized name: vadadustat 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 450 mg once daily (QD)
Trial: 29672740
Drug: Vadadustat 450
RxNorm normalized name: vadadustat 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 450 mg thrice weekly (TIW)
Trial: 29672740
Drug: Overall (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (all dose cohorts)
Trial: 29633515
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel (35 mg/m2 weekly or 75 mg/m2 every 3 weeks)
Trial: 25073921
Drug: Buffered saline
RxNorm normalized name: Phosphate Buffered Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered saline solution
Trial: 17511155
Drug: Compositae salviae
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compositae salviae dropping pill (CSDP)
Trial: 11874410
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral hydrocortisone replacement (15 mg at 0800, 5 mg at 1700)
Trial: 7562888
Drug: Nifedipine-GITS 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine-GITS 30 mg
Trial: 2161295
Drug: Carboplatin 300
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 300 or 400 mg/m2 every 4 weeks
Trial: 7315769
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no fluoride supplements)
Trial: 7315769
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg fluoride as sodium fluoride
Trial: 7315769
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg fluoride as sodium fluoride
Trial: 26481215
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m² and bevacizumab 15 mg/kg (Level 0 cohort)
Trial: 26481215
Drug: Docetaxel 50
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 50 mg/m² and bevacizumab 15 mg/kg (Level 1 cohort)
Trial: 22873656
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus metronidazole (375 mg amoxicillin and 500 mg metronidazole, three times daily for 7 days)
Trial: 8473551
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of clentiazem (20 mg)
Trial: 8473551
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) administration of clentiazem (80 mg)
Trial: 2869591
Drug: Somatostatin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (250 micrograms bolus followed by 300 micrograms/hr infusion)
Trial: 28595285
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without bevacizumab (Control)
Trial: 29694465
Drug: Melatonin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (12 mg/day)
Trial: 25516139
Drug: 200,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200,000 IU vitamin D3 monthly for two months then 100,000 IU monthly for a total of 18 months
Trial: 18728266
Drug: Allopurinol, 200
RxNorm normalized name: Allopurinol, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol, 200 mg twice daily for 4 weeks
Trial: 14651755
Drug: Evidence Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence Based Medicine (EBM) Knowledge Score; average score on the 12-point scale was 6.4; over 50% of respondents answered questions satisfactorily regarding critical appraisal methods and interpretation of results.
Trial: 28386694
Drug: Alcohol (1.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.09 g ethanol kg-1 fat-free body mass)
Trial: 15023830
Drug: Acupuncture (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (up to 12 treatments over three months)
Trial: 11779264
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/d or 120 mg/d)
Trial: 9555668
Drug: Intravenous iron-saccharate
RxNorm normalized name: Iron saccharate
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron-saccharate and rhEPO treatment in group II patients
Trial: 9555668
Drug: Intravenous iron-saccharate
RxNorm normalized name: Iron saccharate
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron-saccharate and rhEPO treatment in group IV patients
Trial: 8288664
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 grams followed by 750 mg at 8 and 16 hours later for a total of one day)
Trial: 8288664
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 gram every 8 hours for 9 doses for a total of three days)
Trial: 31317534
Drug: Standardized antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized antibiotic stewardship quality improvement program
Trial: 31378975
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal therapy (SPT) consisting of oral prophylaxis with oral hygiene instructions
Trial: 31378975
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal therapy (SPT) combined with subgingival instrumentation
Trial: 31378975
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal therapy (SPT)
Trial: 27862178
Drug: rHSA/IFNα2a 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHSA/IFNα2a 600 μg
Trial: 11218544
Drug: male and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: male and female condom plus N-9 products (vaginal suppositories, film, gel)
Trial: 29271855
Drug: Lidocaine Spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine Spray (LS)
Trial: 19290703
Drug: Standard methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methadone treatment
Trial: 11036470
Drug: Dose-intense M-VAC
RxNorm normalized name: M-2698
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intense M-VAC with G-CSF support
Trial: 11036470
Drug: Conventional-dose M-VAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose M-VAC
Trial: 8977854
Drug: Antral washouts
RxNorm normalized name: ALCOHOL 64.7 g in 100 g TOPICAL GEL [Astral Organica Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antral washouts followed by antibiotics and topical nasal steroids
Trial: 6242801
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified porcine insulin zinc suspension (mixed)
Trial: 18329126
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily plus placebo (monotherapy)
Trial: 15949731
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with full-dose ATG regimen (Merieux) for 8 days
Trial: 2668140
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ruscus extract and HMC
Trial: 12611746
Drug: Donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10 mg/day)
Trial: 15098800
Drug: Oxymorphone extended
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone extended release (ER) 5 mg
Trial: 15098800
Drug: Oxymorphone extended
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone extended release (ER) 10 mg
Trial: 15098800
Drug: Oxymorphone extended
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone extended release (ER) 10 mg every 12 hrs
Trial: 15098800
Drug: Oxymorphone extended
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone extended release (ER) 20 mg every 12 hrs
Trial: 15098800
Drug: Oxymorphone extended
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone extended release (ER) 40 mg every 12 hrs
Trial: 8179173
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia (GA) with 0.1‐0.15 mg/kg midazolam and 10 micrograms/kg fentanyl prior to skin incision; maintenance included 65% nitric oxide in oxygen and 0.1 mg increments of fentanyl as required.
Trial: 8179173
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg i.v.) administered 15 min before induction of anaesthesia.
Trial: 8179173
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (no ibuprofen).
Trial: 3035164
Drug: Sodium bicarbonate,
RxNorm normalized name: Sodium Bicarbonate, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate, hydrogen peroxide, and sodium chloride (S/P) oral hygiene
Trial: 3035164
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral hygiene procedures plus phase‐contrast demonstration
Trial: 3035164
Drug: S/P oral
RxNorm normalized name: paregor/salol/Psn Ac/bism ss/p ORAL SUSPENSION, ORAL (FINAL DOSE FORM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/P oral hygiene plus phase‐contrast demonstration
Trial: 30064986
Drug: Heparin bridging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bridging
Trial: 19793142
Drug: Uninterrupted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted warfarin
Trial: 3358822
Drug: Parenteral thiamin
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral thiamin supplementation (250 mg daily for 5 days)
Trial: 3358822
Drug: Parenteral thiamin
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral thiamin supplementation (250 mg within 24 hr)
Trial: 29490101
Drug: Omega‐3‐6‐9 Junior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega‐3‐6‐9 Junior (Nordic Naturals, Inc.) treatment (338 mg eicosapentaenoic acid, 225 mg DHA, and 83 mg GLA)
Trial: 29490101
Drug: Canola oil
RxNorm normalized name: Canola Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canola oil (124 mg palmitic acid, 39 mg stearic acid, 513 mg linoleic acid, 225 mg α‐linolenic acid, and 1346 mg oleic acid)
Trial: 24815101
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (COCs)
Trial: 9428849
Drug: Remifentanil 3-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 3-4 micrograms/kg and propofol 2 mg/kg
Trial: 8291918
Drug: CPT-11 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (irinotecan hydrochloride) regimen B (40 mg/m2 for 5 days every 3-4 weeks)
Trial: 8291918
Drug: CPT-11 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (irinotecan hydrochloride) regimen C (40 mg/m2 for 3 days every week)
Trial: 8291918
Drug: CPT-11 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (irinotecan hydrochloride) regimen D (20 mg/m2 twice a day for 7 days every 3-4 weeks)
Trial: 8291918
Drug: CPT-11 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (irinotecan hydrochloride) regimen A (200 mg/m2 once a day every 3-4 weeks)
Trial: 17065352
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg uric acid i.v. in vehicle
Trial: 17065352
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg vitamin C as a control antioxidant
Trial: 9286047
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccines containing genetically detoxified PT
Trial: 1390504
Drug: Aspirin 1200
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1200 mg/day
Trial: 4009497
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (urine pH 5.6)
Trial: 31497876
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment
Trial: 11864514
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 550 +/- 150 mg/d
Trial: 11864514
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 900 +/- 150 mg/d
Trial: 11864514
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 1500 +/- 150 mg/d
Trial: 27264413
Drug: Low-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity statin therapy
Trial: 27885786
Drug: Medium chain
RxNorm normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium chain triglycerides (MCT) oil (6 g/d for 8 weeks)
Trial: 25869389
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 5 mg once daily for 4 weeks, then every other day for an additional 4 weeks
Trial: 25869389
Drug: Prednisone (PD)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PD) 40 mg once daily for the initial 2 weeks, tapered by 10 mg every 2 weeks during the 8-week study period
Trial: 14758179
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus intravascular catheter-based heat exchange system (Alsius, Irvine, CA)
Trial: 14758179
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (acetaminophen and cooling blankets)
Trial: 11419818
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 20 wk
Trial: 11419818
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg b.i.d. for 20 wk
Trial: 11419818
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg b.i.d. for 8 wk followed by lansoprazole 30 mg once daily for 12 wk ('step-up')
Trial: 11419818
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 8 wk followed by ranitidine 150 mg b.i.d. for 12 wk ('step-down')
Trial: 8474318
Drug: 46 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 46 g parboiled white rice
Trial: 8474318
Drug: 69 g
RxNorm normalized name: DIMETHICONE 3.69 g in 55 g CUTANEOUS CREAM [GOLDKIWI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 69 g parboiled white rice
Trial: 20107198
Drug: High Fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Fat diet (low-carbohydrate diet < or =20 g/d)
Trial: 18046669
Drug: 4.0 g
RxNorm normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g daily sevelamer dose
Trial: 18046669
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g daily sevelamer dose
Trial: 2208013
Drug: Immediate combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate combination chemotherapy
Trial: 352507
Drug: CP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP (cyclophosphamide 1 g/m2 on day 1 and prednisone 100 mg/m2 daily for five days)
Trial: 352507
Drug: BCVP (CVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCVP (CVP plus BCNU 60 mg/m2 on day 1)
Trial: 19117121
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g etofenamate (group 1)
Trial: 16076380
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride 2250 mg/day
Trial: 16076380
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride 3000 mg/day
Trial: 10072008
Drug: Spinal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg + clonidine 50 microg
Trial: 10072008
Drug: Spinal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg
Trial: 7575051
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mg nicotine polacrilex)
Trial: 23729801
Drug: Ofatumumab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab 0.3 mg